Bettina M. Cockroft - 14 Sep 2023 Form 4/A - Amendment Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role
Director
Signature
/s/ Christopher Downs, Attorney-in-fact
Issuer symbol
CNSP
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
12 Oct 2023, 18:00:10 UTC
Date Of Original Report
25 Sep 2023
Previous filing
12 Jun 2023
Next filing
25 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNSP Option to purchase common stock Award +6,500 +310% 8,599 14 Sep 2023 Common Stock 6,500 $2.27 Direct F1, F2
transaction CNSP Option to purchase common stock Award +9,475 +110% 18,074 21 Sep 2023 Common Stock 9,475 $1.09 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options set forth in this table vest in 36 equal monthly installments. The stock option was approved by the compensation committee of the company's board of directors on August 4, 2023, subject to shareholder approval of the 2020 Stock Plan under which the option was granted. The shareholders of the company approved the plan at the company's annual meeting on September 14, 2023.
F2 The stock options were issued in connection with the reporting person's Board of Director services to the Company.
F3 The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Remarks:

This amendment is being filed solely to correct the number of shares of common stock underlying the reported option issued on September 21, 2023, and the total number of derivative securities owned following the reported transaction.